Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies

Dong Yi Chen, Jia Rou Liu, Chi Nan Tseng, Ming Jer Hsieh, Cheng Keng Chuang, See Tong Pang, Shao Wei Chen, I. Chang Hsieh, Pao Hsien Chu, Jen Shi Chen, John Wen-Cheng Chang, Wen Kuan Huang*, Lai Chu See*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

11 Scopus citations


Background: The risk for major adverse cardiovascular events (MACE) with targeted therapies for patients with advanced renal cell carcinoma (RCC) in real-world practice remains unclear. Objectives: The aim of this study was to compare the risk for MACE associated with targeted cancer therapies with that associated with cytokine treatment in patients with advanced RCC. Methods: Using Taiwan's National Health Insurance Research Database, a retrospective nationwide cohort study was conducted involving patients with advanced RCC who had received targeted therapy (sunitinib, sorafenib, pazopanib, everolimus, or temsirolimus) or cytokine therapy (interleukin-2 or interferon gamma) from 2007 to 2018. Cox proportional hazards models were used to estimate the risk for MACE (a composite of myocardial infarction, ischemic stroke, heart failure, and cardiovascular death) in the cohort using the propensity score method of stabilized inverse probability of treatment weighting. Results: In this cohort of 2,785 patients with advanced RCC, 2,257 (81%) and 528 (19%) had received targeted and cytokine therapy, respectively. After stabilized inverse probability of treatment weighting, the incidence rates of MACE were 6.65 and 3.36 per 100 person-years in the targeted and cytokine therapy groups, respectively (HR: 1.80; 95% CI: 1.19-2.74). Baseline history of heart failure (HR: 3.88; 95% CI: 2.25-6.71), atrial fibrillation (HR: 3.60; 95% CI: 2.16-5.99), venous thromboembolism (HR: 2.50; 95% CI: 1.27-4.92), ischemic stroke (HR: 1.88; 95% CI: 1.14-3.11), and age ≥ 65 years (HR: 1.81; 95% CI: 1.27-2.58) were independent risk factors for targeted therapy–associated MACE. Conclusions: Among patients with advanced RCC, the risk for MACE associated with targeted cancer therapy is higher than that associated with cytokine therapy.

Original languageEnglish
Pages (from-to)223-234
Number of pages12
JournalJACC: CardioOncology
Issue number2
StatePublished - 06 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors


  • cardiovascular toxicity
  • renal cell carcinoma
  • targeted cancer therapy


Dive into the research topics of 'Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies'. Together they form a unique fingerprint.

Cite this